Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Propafenone Use in Structural Heart Disease and Heart Failure

Contraindications and Alternative Options

  • The European Heart Journal recommends that propafenone should be completely avoided in patients with heart failure or reduced left ventricular ejection fraction 1, 2, 3
  • The European Heart Journal suggests that amiodarone is the preferred antiarrhythmic agent in patients with structural heart disease, including those with heart failure 4, 5
  • Sotalol may be used in patients with ischemic heart disease but without severe heart failure, as recommended by the European Heart Journal 5

Monitoring and Risk Assessment

  • Regular ECG monitoring is essential during initiation and dose adjustments of propafenone in patients with mild structural abnormalities, as recommended by the European Heart Journal 5
  • Monitor for QRS prolongation; an increase in QRS duration >25% from baseline indicates potential proarrhythmic risk, according to the European Heart Journal 5

Mechanisms of Risk

  • Propafenone can precipitate ventricular tachycardia, ventricular fibrillation, and intraventricular conduction disturbances, as reported in Circulation 2